Well, almost. Proposals are out for consultation. The consultation document is 62 pages long…6 pages of intro, 10 page summary, 6 pages of questions, 40 pages of detail. There’s also a one hour webinar coming up. But if all of that is too much, here’s our handy summary:
- End of life is out
- Severity and inequalities are in as factors that could modify the threshold ICER
- Greater emphasis on real world data and expert elicitation
- 5L mapping using the DSU tool
- EVPI is routine…but not mandatory?
- Potential role for ‘cost comparison analysis’….cost-minimisation analysis
And if that’s too much for all you busy pharma company executives out there, just lower your prices and you won’t have any problems.
Details and registration for a webinar on the 25th November are available here.
Simon Dixon